| abstract |
FIELD: medicine, oncology, pharmacology. SUBSTANCE: preparation involves the local use of torimefene or one of its metabolites N-demethyltorimefene or 4-hydroxytorimefene as an active component or their pharmaceutically acceptable nontoxic salts for treatment of patients with malignant tumors located in skin or at small distance from skin, for example, metastatic formations of breast cancer. The preparation can be used also for additional curative aims in breast cancer and in alternated multidrug resistance of cancer cells to cytotoxic drugs. These local preparations have the special importance for treatment of patients with melanoma and lymphoma. EFFECT: decreased adverse effects in treatment. 9 cl, 4 dwg, 7 tbl, 5 ex |